menu
    • menu

    Company profile for Vico Therapeutics

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Bringing knowledge, experience and science together to discover, develop and deliver therapies for CNS disorders. Vico was founded in Q4 2019 by the highly experienced entrepreneurs Luc Dochez and Josh Mandel-Brehm and seasoned scientists Dr. Judith van Deutekom and Dr. Gail Mandel with strong academic reputations and vast industry experience.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Vico TherapeuticsNetherlands1 Flag
    Country
    Country
    Netherlands
    Address
    Address
    BioScience Park BioPartner Building 1 J.H. Oortweg 21 2333 CH Leiden The Nethe...
    Telephone
    Telephone
    +31 71 2036800
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://vicotx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/vico-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Vico Therapeutics Announces Positive VO659 Data In Huntington's Disease
    Vico Therapeutics Announces Positive VO659 Data In Huntington's Disease

    13 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/vico-therapeutics-announces-positive-interim-phase-12a-clinical-data-of-vo659-in-treatment-of-huntingtons-disease-302247239.html

    PR NEWSWIRE
    13 Sep 2024
    Share Share
    Seroba and Kurma Partners Announce Complementary Series B Funding for Vico
    Seroba and Kurma Partners Announce Complementary Series B Funding for Vico

    24 Jun 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240623484065/en

    BUSINESSWIRE
    24 Jun 2024
    Share Share
    Vico Announces First Patient Dosed in Phase 1/2a Clinical Trial of VO659
    Vico Announces First Patient Dosed in Phase 1/2a Clinical Trial of VO659

    03 Apr 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/vico-therapeutics-announces-first-patient-dosed-in-phase-12a-clinical-trial-of-vo659-in-huntingtons-disease-and-spinocerebellar-ataxia-types-1-and-3-301787046.html

    PR NEWSWIRE
    03 Apr 2023
    Share Share
    US FDA grants VICO Therapeutics Orphan-Drug Designation for VO659
    US FDA grants VICO Therapeutics Orphan-Drug Designation for VO659

    29 Jul 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/us-fda-grants-vico-therapeutics-orphan-drug-designation-for-vo659-an-investigational-therapy-for-huntington-disease-301343993.html

    PRNEWSWIRE
    29 Jul 2021
    Share Share
    EC Grants Orphan Drug Designation to Vico Therapeutics’ Oligonucleotide SCA
    EC Grants Orphan Drug Designation to Vico Therapeutics’ Oligonucleotide SCA

    11 Feb 2021

    // PHARMTECH

    https://www.pharmtech.com/view/ec-grants-orphan-drug-designation-to-vico-therapeutics-oligonucleotide-sca-therapy

    PHARMTECH
    11 Feb 2021
    Share Share
    Vico Therapeutics’ antisense oligonucleotide therapy, VO659
    Vico Therapeutics’ antisense oligonucleotide therapy, VO659

    11 Feb 2021

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=135463&sid=2

    PHARMABIZ
    11 Feb 2021
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search